title: Effects of locoregional radiotherapy in patients with metastatic breast cancer.
abstract: OBJECTIVE
  This study aims to assess the clinical outcomes of patients with metastatic breast cancer (MBC) who underwent local radiation therapy (RT) for the primary site.
  
  
  METHODS
  Between 2005 and 2013, we retrospectively evaluated patients with MBC who received breast or chest wall RT with or without regional lymph node irradiation.
  
  
  RESULTS
  2761 patients with breast cancer were treated with RT. Of them, 125 women with stage IV breast carcinoma were included. The median follow-up was 15 months (ranging from 3.8 to 168 months), when 54.7% of the patients had died; local progression was observed in 22.8% of the patients. The mean overall survival (OS) and local progression free survival (LoPFS) were 23.4 ± 2.4 months and 45.1 ± 2.9 months, respectively. Three- and five-year overall survival rates were, respectively, 21.2% and 13.3%. Local progression free survival was the same, 67.3%, at three and five years, respectively. Karnofsky Performance Status (KPS) (p = 0.015), number of metastatic sites (p = 0.031), RT dose (p = 0.0001) and hormone therapy (p = 0.0001) were confirmed as independent significant variables correlated with OS. The variables that were independently correlated with LoPFS were the number of previous chemotherapy lines (p = 0.038) and RT dose (p = 0.0001).
  
  
  CONCLUSIONS
  RT of the primary site in patients with MBC is well tolerated. The factors that presented positive impact on survival were good KPS, low disease burden (1-3 metastatic sites), and the use of hormone therapy.
authors.affiliation: Department of Radiology and Oncology of University of São Paulo, Instituto de Radiologia do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo and Instituto do Câncer do Estado de São Paulo (ICESP), Av. Dr. Arnaldo, 251, Cerqueira César, Sao Paulo - SP, 01246-000, Brazil. Electronic address: geovanne95@gmail.com.
authors.forename: Geovanne Pedro
authors.initials: GP
authors.lastname: Mauro
authors.affiliation: Department of Radiology and Oncology of University of São Paulo, Instituto de Radiologia do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo and Hospital Sírio-Libanês, Brazil, Av. Dr. Arnaldo, 251, Cerqueira César, Sao Paulo - SP, 01246-000, Brazil. Electronic address: heloisa.carvalho@hc.fm.usp.br.
authors.forename: Heloisa
authors.initials: H
authors.lastname: de Andrade Carvalho
authors.affiliation: Department of Radiology and Oncology of University of São Paulo, Instituto de Radiologia do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Av. Dr. Arnaldo, 251, Cerqueira César, Sao Paulo - SP, 01246-000, Brazil. Electronic address: srstuart@uol.com.br.
authors.forename: Silva Radwanski
authors.initials: SR
authors.lastname: Stuart
authors.affiliation: Department of Radiology and Oncology of University of São Paulo, Instituto do Câncer do Estado de São Paulo (ICESP) - Faculdade de Medicina da Universidade de São Paulo and Hospital Sírio-Libanês, Brazil, Av. Dr. Arnaldo, 251, Cerqueira César, Sao Paulo - SP, 01246-000, Brazil. Electronic address: max.mano@usp.br.
authors.forename: Max Senna
authors.initials: MS
authors.lastname: Mano
authors.affiliation: Department of Radiology and Oncology of University of São Paulo, Instituto do Câncer do Estado de São Paulo (ICESP) - Faculdade de Medicina da Universidade de São Paulo and Hospital Sírio-Libanês, Brazil, Av. Dr. Arnaldo, 251, Cerqueira César, Sao Paulo - SP, 01246-000, Brazil. Electronic address: gnmarta@uol.com.br.
authors.forename: Gustavo Nader
authors.initials: GN
authors.lastname: Marta
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy*; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy / Q000532:radiotherapy* / Q000556:secondary*; D018275:Carcinoma, Lobular / Q000188:drug therapy / Q000532:radiotherapy* / Q000556:secondary*; D017024:Chemotherapy, Adjuvant; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D000069473:Radiation Dose Hypofractionation; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D018931:Antineoplastic Agents, Hormonal
keywords: Breast cancer; Metastases; Radiation therapy; Stage IV; Treatment